A citation-based method for searching scientific literature

J M van Berge Henegouwen, M Jebbink, L R Hoes, H van der Wijngaart, L J Zeverijn, D L van der Velden, P Roepman, W W J de Leng, A M L Jansen, E van Werkhoven, V van der Noort, A J van der Wekken, A J de Langen, E E Voest, H M W Verheul, E F Smit, H Gelderblom. Eur J Cancer 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Recent advances in the HER2 targeted therapy of gastric cancer.
Tasuku Matsuoka, Masakazu Yashiro. World J Clin Cases 2015
33
100

HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.
Heike Grabsch, Shivan Sivakumar, Sally Gray, Helmut E Gabbert, Wolfram Müller. Cell Oncol 2010
216
100

Comprehensive Characterization of Cancer Driver Genes and Mutations.
Matthew H Bailey, Collin Tokheim, Eduard Porta-Pardo, Sohini Sengupta, Denis Bertrand, Amila Weerasinghe, Antonio Colaprico, Michael C Wendl, Jaegil Kim, Brendan Reardon,[...]. Cell 2018
901
100


Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Xue-Wu Wei, Xin Gao, Xu-Chao Zhang, Jin-Ji Yang, Zhi-Hong Chen, Yi-Long Wu, Qing Zhou. Thorac Cancer 2020
16
100

Erlotinib in previously treated non-small-cell lung cancer.
Frances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins,[...]. N Engl J Med 2005
100

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, Gérard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Céline Mascaux,[...]. J Clin Oncol 2022
14
100

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.
Fiamma Buttitta, Fabio Barassi, Giuseppina Fresu, Lara Felicioni, Antonio Chella, Diego Paolizzi, Giuseppe Lattanzio, Simona Salvatore, Pier P Camplese, Sandra Rosini,[...]. Int J Cancer 2006
132
100

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla,[...]. Eur J Cancer 2021
29
100

The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Eun Kyung Kim, Kyung A Kim, Chang Young Lee, Hyo Sup Shim. PLoS One 2017
51
100

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Maria E Arcila, Jamie E Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K Paik, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
296
100

Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
Eiji Iwama, Yoshitaka Zenke, Shunichi Sugawara, Haruko Daga, Masahiro Morise, Noriko Yanagitani, Tomohiro Sakamoto, Haruyasu Murakami, Junji Kishimoto, Shingo Matsumoto,[...]. Eur J Cancer 2022
5
100

Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
Kanika Bajaj Pahuja, Thong T Nguyen, Bijay S Jaiswal, Kumar Prabhash, Tarjani M Thaker, Kate Senger, Subhra Chaudhuri, Noelyn M Kljavin, Aju Antony, Sameer Phalke,[...]. Cancer Cell 2018
63
100

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Richard Bell, Christian Jackisch,[...]. N Engl J Med 2005
100

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Adriana Estrada-Bernal, Anh T Le, Andrea E Doak, Vijaya G Tirunagaru, Shevan Silva, Matthew R Bull, Jeff B Smaill, Adam V Patterson, Chul Kim, Stephen V Liu,[...]. Clin Cancer Res 2021
35
100

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, John Bryant, Vera J Suman, Charles E Geyer, Nancy E Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A Kaufman,[...]. N Engl J Med 2005
100

Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.
Han Han, Shuai Li, Ting Chen, Michael Fitzgerald, Shengwu Liu, Chengwei Peng, Kwan Ho Tang, Shougen Cao, Johara Chouitar, Jiansheng Wu,[...]. Cancer Res 2021
11
100

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang, C Rivard, G Gao, T L Ng, M M Tu,[...]. Ann Oncol 2019
107
100

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Hyun-Soo Cho, Karen Mason, Kasra X Ramyar, Ann Marie Stanley, Sandra B Gabelli, Dan W Denney, Daniel J Leahy. Nature 2003
100

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
Jacques De Grève, Teresa Moran, Marie-Pascale Graas, Daniella Galdermans, Peter Vuylsteke, Jean-Luc Canon, Denis Schallier, Lore Decoster, Erik Teugels, Dan Massey,[...]. Lung Cancer 2015
63
100

HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
Petra Heinmöller, Christof Gross, Kurt Beyser, Claudia Schmidtgen, Gerd Maass, Michele Pedrocchi, Josef Rüschoff. Clin Cancer Res 2003
121
100

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.
Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, Mehmet Altan, Don L Gibbons, Frank V Fossella, Vincent K Lam, Anisha B Patel, Marcelo V Negrao, Xiuning Le,[...]. J Clin Oncol 2022
25
100

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
Yan Wang, Shijia Zhang, Fengying Wu, Jing Zhao, Xuefei Li, Chao Zhao, Shengxiang Ren, Caicun Zhou. BMC Cancer 2018
28
100

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
Caicun Zhou, Xingya Li, Qiming Wang, Guanghui Gao, Yiping Zhang, Jianhua Chen, Yongqian Shu, Yanping Hu, Yun Fan, Jian Fang,[...]. J Clin Oncol 2020
68
100

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib.
Nishan Tchekmedyian, Bill Paxton, Francois Lebel, Lena Keossayan, John V Heymach. JTO Clin Res Rep 2020
1
100

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim,[...]. Cancer Res Treat 2018
46
100

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
500
100

Mutational landscape and significance across 12 major cancer types.
Cyriac Kandoth, Michael D McLellan, Fabio Vandin, Kai Ye, Beifang Niu, Charles Lu, Mingchao Xie, Qunyuan Zhang, Joshua F McMichael, Matthew A Wyczalkowski,[...]. Nature 2013
100

Genomic alterations of ERBB receptors in cancer: clinical implications.
Rosalin Mishra, Ariella B Hanker, Joan T Garrett. Oncotarget 2017
63
100

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, Brittany E Harvey, Pamela B Mangu, John M S Bartlett, Michael Bilous, Ian O Ellis, Patrick Fitzgibbons, Wedad Hanna,[...]. J Clin Oncol 2018
737
100

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
100

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Jacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, Brett W Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal,[...]. Nat Med 2018
236
100

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib.
Bo Yuan, Jun Zhao, Chengzhi Zhou, Xiumei Wang, Bo Zhu, Minglei Zhuo, Xilin Dong, Jiemei Feng, Cuihua Yi, Yunpeng Yang,[...]. Front Oncol 2020
8
100


Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi. Clin Lung Cancer 2018
17
100

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
Kiichiro Ninomiya, Tae Hata, Hiroshige Yoshioka, Kadoaki Ohashi, Akihiro Bessho, Shinobu Hosokawa, Nobuhisa Ishikawa, Masahiro Yamasaki, Takuo Shibayama, Keisuke Aoe,[...]. Chest 2019
24
100

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Solange Peters, Rolf Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M Kowalski, Christina S Baik, Dolores Isla, Javier De Castro Carpeno, Pilar Garrido,[...]. Clin Cancer Res 2019
105
100

EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Federico Cappuzzo, Claudia Ligorio, Luca Toschi, Elisa Rossi, Rocco Trisolini, Daniela Paioli, Elisabetta Magrini, Giovanna Finocchiaro, Stefania Bartolini, Alessandra Cancellieri,[...]. J Thorac Oncol 2007
63
100

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, Lisa M Crocker, Kathryn L Parsons, Elaine Mai, Walter A Blättler, John M Lambert, Ravi V J Chari, Robert J Lutz,[...]. Cancer Res 2008
100

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Julien Mazières, Solange Peters, Benoit Lepage, Alexis B Cortot, Fabrice Barlesi, Michéle Beau-Faller, Benjamin Besse, Hélène Blons, Audrey Mansuet-Lupo, Thierry Urban,[...]. J Clin Oncol 2013
430
100

Consensus for HER2 alterations testing in non-small-cell lung cancer.
S Ren, J Wang, J Ying, T Mitsudomi, D H Lee, Z Wang, Q Chu, P C Mack, Y Cheng, J Duan,[...]. ESMO Open 2022
5
100

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.
Shengwu Liu, Shuai Li, Josephine Hai, Xiaoen Wang, Ting Chen, Max M Quinn, Peng Gao, Yanxi Zhang, Hongbin Ji, Darren A E Cross,[...]. Clin Cancer Res 2018
59
100

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy,[...]. J Thorac Oncol 2020
112
100


Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.
Wenhsiang Wen, Wangjuh Sting Chen, Nick Xiao, Ryan Bender, Anatole Ghazalpour, Zheng Tan, Jeffrey Swensen, Sherri Z Millis, Gargi Basu, Zoran Gatalica,[...]. J Mol Diagn 2015
39
100

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M Clarke, Nishan Tchekmedyian, Jonathan W Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V Heymach,[...]. J Clin Oncol 2022
21
100

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.
Umair Majeed, Rami Manochakian, Yujie Zhao, Yanyan Lou. J Hematol Oncol 2021
37
100

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Rathi N Pillai, Madhusmita Behera, Lynne D Berry, Mike R Rossi, Mark G Kris, Bruce E Johnson, Paul A Bunn, Suresh S Ramalingam, Fadlo R Khuri. Cancer 2017
88
100

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
W Victoria Lai, Louisiane Lebas, Tristan A Barnes, Julie Milia, Ai Ni, Oliver Gautschi, Solange Peters, Roberto Ferrara, Andrew J Plodkowski, John Kavanagh,[...]. Eur J Cancer 2019
54
100

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang,[...]. Oncologist 2019
22
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.